When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK ... - AOL

   www.aol.com/news/pharma-stock-roundup-fda...

   FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.

3. Large Cap Pharma, Biotech Stocks Down on Regulatory Updates - AOL

   www.aol.com/news/large-cap-pharma-biotech-stocks...

   Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

4. Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer ... - AOL

   www.aol.com/news/pharma-stock-roundup-fda...

   For premium support please call: 800-290-4726 more ways to reach us

5. Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX ... - AOL

   www.aol.com/news/pharma-stock-roundup-fda-panels...

   An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.

6. Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK ... - AOL

   www.aol.com/news/pharma-stock-roundup-mrk-azn...

   For premium support please call: 800-290-4726 more ways to reach us

7. List of largest biomedical companies by revenue - Wikipedia

   en.wikipedia.org/wiki/List_of_largest_biomedical...

   The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.

8. Pharma Stock Roundup: J&J's Mixed Q1 Results, FDA Updates for ...

   www.aol.com/news/pharma-stock-roundup-j-js...

   For premium support please call: 800-290-4726 more ways to reach us

9. List of largest pharmaceutical mergers and acquisitions

   en.wikipedia.org/wiki/List_of_largest...

   Takeda Pharmaceutical: Shire: 61 74 Second bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] 12 2018 Takeda Pharmaceutical: Shire: 58.2 71